Precipio, Inc. Annual Report: A Simple Breakdown

I’ve put together this guide to help you understand how Precipio, Inc. performed this year. My goal is to translate their complex filings into plain English so you can decide if this company fits your investment goals.

1. What does this company do?

Precipio is a healthcare company based in New Haven, Connecticut, focused on solving the problem of cancer misdiagnosis. They operate two divisions that act as a self-funding engine:

• Pathology Services: They run a specialized lab that tests for blood cancers. In 2025, this division brought in about $6.8 million, providing the cash needed to support their operations.
• Products Division: They develop and sell diagnostic tools. This includes high-profit kits like the HemeScreen panel and IV-Cell culture media, which help hospitals and labs work more accurately and efficiently.

2. Their "Secret Sauce"

Precipio uses its own lab to test and improve its products in real-time. This gives them a speed advantage. They see what doctors need today and build solutions faster than competitors who lack direct access to patient samples. By using their lab as a testing ground, they cut their development time by 30–40% compared to traditional companies.

3. The Product Edge

• HemeScreen: This is a faster, cheaper alternative to complex genetic testing. Standard tests check 50–500 genes, but HemeScreen focuses on the 4–7 genes actually needed for a diagnosis. Because it is cost-effective, it fits better with insurance payment rules, making it easier for labs to adopt.
• IV-Cell: This "universal" media lets labs grow all four types of blood cells at once. It cuts labor time by about 20% and reduces the risk of sample failure, which is a major headache for busy labs.

4. Financial Health: The "Going Concern" Warning

This is the most important section. While the company generated $0.7 million in cash from operations in 2025, they remain in a fragile state.

• The "Going Concern" Flag: Auditors issued a warning that the company may not have enough cash to cover its bills and debts for the next 12 months.
• The Numbers: By the end of 2025, the company had lost $102.8 million over its lifetime and held only $2.6 million in cash. With a monthly cash burn of $0.4 million, they have roughly 6–7 months of runway left without raising more money.
• The Path Forward: Survival depends on selling more products to reach a break-even point. Management is looking for new investors, debt restructuring, or partners. If they fail to raise money or grow sales, they may have to cut costs, which could impact their lab certifications and product development.

5. Major Risks

Beyond their financial struggles, they face several hurdles:

• Regulatory & Privacy: They must follow strict healthcare data laws. A data breach or the loss of lab certifications would immediately shut down their main source of income.
• Concentration Risk: Much of their revenue comes from a few insurance providers and government programs like Medicare. If these groups cut their payment rates, Precipio’s revenue would drop immediately.
• Competition: They compete against giants like LabCorp and Quest. These companies have massive budgets and established sales teams. Precipio struggles to gain market share because they lack the cash to compete on marketing.

Bottom Line: Precipio is a high-risk, "all-or-nothing" investment. They have a clever product strategy, but they are running low on cash and must scale their sales quickly to survive. Before investing, consider whether you are comfortable with a company that relies on near-term capital raises to maintain its operations.